{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T04:59:23Z","timestamp":1790398763998,"version":"4.1.0"},"reference-count":83,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.cgh.2020.04.091","type":"journal-article","created":{"date-parts":[[2020,5,17]],"date-time":"2020-05-17T02:03:25Z","timestamp":1589681005000},"page":"2006-2014","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":76,"title":["Should Treatment Indications for Chronic Hepatitis B Be Expanded?"],"prefix":"10.1016","volume":"19","author":[{"given":"Wen-Juei","family":"Jeng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5811-6845","authenticated-orcid":false,"given":"Anna S.","family":"Lok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2020.04.091_bib1","series-title":"Global hepatitis report, 2017","year":"2017"},{"key":"10.1016\/j.cgh.2020.04.091_bib2","doi-asserted-by":"crossref","first-page":"773","DOI":"10.15585\/mmwr.mm6728a2","article-title":"Access to treatment for hepatitis B virus infection: worldwide, 2016","volume":"67","author":"Hutin","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.cgh.2020.04.091_bib3","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2020.04.091_bib4","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"Electronic address eee, European Association for the Study of the Liver: EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2020.04.091_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","article-title":"Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update","volume":"10","author":"Sarin","year":"2016","journal-title":"Hepatol Int"},{"key":"10.1016\/j.cgh.2020.04.091_bib6","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/hep.28156","article-title":"AASLD guidelines for treatment of chronic hepatitis B","volume":"63","author":"Terrault","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2020.04.091_bib7","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1111\/liv.13253","article-title":"Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients","volume":"36","author":"Su","year":"2016","journal-title":"Liver Int"},{"key":"10.1016\/j.cgh.2020.04.091_bib8","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jhep.2018.10.014","article-title":"HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues","volume":"70","author":"Yip","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2020.04.091_bib9","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1053\/j.gastro.2008.05.031","article-title":"Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b","volume":"135","author":"Buster","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2020.04.091_bib10","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1056\/NEJMoa043470","article-title":"Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B","volume":"352","author":"Lau","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2020.04.091_bib11","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/hep.24555","article-title":"Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C","volume":"54","author":"Liaw","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2020.04.091_bib12","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0140-6736(05)17701-0","article-title":"Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial","volume":"365","author":"Janssen","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2020.04.091_bib13","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1053\/j.gastro.2009.03.006","article-title":"Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a","volume":"136","author":"Marcellin","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2020.04.091_bib14","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1111\/liv.14155","article-title":"Ten-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B virus infection","volume":"39","author":"Marcellin","year":"2019","journal-title":"Liver Int"},{"key":"10.1016\/j.cgh.2020.04.091_bib15","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1002\/hep.29497","article-title":"Significance of definitions of relapse after discontinuation of oral antivirals in HBeAg-negative chronic hepatitis B","volume":"68","author":"Papatheodoridis","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2020.04.091_bib16","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1002\/hep.29320","article-title":"The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B","volume":"66","author":"Papatheodoridis","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2020.04.091_bib17","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/hep.29640","article-title":"Incidence and predictors of hepatitis B surface antigen seroclearance after cessation of nucleos(t)ide analogue therapy in hepatitis B e antigen-negative chronic hepatitis B","volume":"68","author":"Jeng","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2020.04.091_bib18","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s12072-019-09991-y","article-title":"Comparison of HBsAg changes between HBeAg-negative patients who discontinued or maintained entecavir therapy","volume":"14","author":"Chen","year":"2020","journal-title":"Hepatol Int"},{"key":"10.1016\/j.cgh.2020.04.091_bib19","doi-asserted-by":"crossref","first-page":"6599","DOI":"10.1073\/pnas.87.17.6599","article-title":"Is a function of the secreted hepatitis B e antigen to induce immunologic tolerance in utero?","volume":"87","author":"Milich","year":"1990","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cgh.2020.04.091_bib20","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/j.immuni.2016.04.008","article-title":"Maternal-derived hepatitis B virus e antigen alters macrophage function in offspring to drive viral persistence after vertical transmission","volume":"44","author":"Tian","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.cgh.2020.04.091_bib21","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1016\/j.jhep.2016.01.026","article-title":"Adaptive immunity in HBV infection","volume":"64","author":"Bertoletti","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2020.04.091_bib22","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/cmi.2014.79","article-title":"The immune tolerant phase of chronic HBV infection: new perspectives on an old concept","volume":"12","author":"Bertoletti","year":"2015","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.cgh.2020.04.091_bib23","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1053\/j.gastro.2012.06.009","article-title":"Preserved T-cell function in children and young adults with immune-tolerant chronic hepatitis B","volume":"143","author":"Kennedy","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2020.04.091_bib24","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1053\/j.gastro.2015.11.050","article-title":"Hepatitis B virus: specific and global T-cell dysfunction in chronic hepatitis B","volume":"150","author":"Park","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2020.04.091_bib25","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1053\/j.gastro.2011.06.036","article-title":"Changes in serum levels of HBV DNA and alanine aminotransferase determine risk for hepatocellular carcinoma","volume":"141","author":"Chen","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2020.04.091_bib26","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1002\/hep.23348","article-title":"Age-specific prognosis following spontaneous hepatitis B e antigen seroconversion in chronic hepatitis B","volume":"51","author":"Chen","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2020.04.091_bib27","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.amjmed.2003.12.040","article-title":"Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels","volume":"116","author":"Chu","year":"2004","journal-title":"Am J Med"},{"key":"10.1016\/j.cgh.2020.04.091_bib28","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1038\/ajg.2009.248","article-title":"Histological disease in Asian-Americans with chronic hepatitis B, high hepatitis B virus DNA, and normal alanine aminotransferase levels","volume":"104","author":"Nguyen","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2020.04.091_bib29","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1111\/jvh.12679","article-title":"Predictors of liver histological changes and a sustained virological response to peginterferon among chronic hepatitis B e antigen-positive patients with normal or minimally elevated alanine aminotransferase levels","volume":"24","author":"Chen","year":"2017","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.cgh.2020.04.091_bib30","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1136\/gutjnl-2017-314904","article-title":"High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B","volume":"67","author":"Kim","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2020.04.091_bib31","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1053\/j.gastro.2005.11.016","article-title":"Predicting cirrhosis risk based on the level of circulating hepatitis B viral load","volume":"130","author":"Iloeje","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2020.04.091_bib32","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jama.295.1.65","article-title":"Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level","volume":"295","author":"Chen","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.cgh.2020.04.091_bib33","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.jhep.2018.01.037","article-title":"Antiviral therapy in hepatitis B virus-infected children with immune-tolerant characteristics: a pilot open-label randomized study","volume":"68","author":"Zhu","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2020.04.091_bib34","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/MPG.0b013e31822a033e","article-title":"Predictive effect of serial serum alanine aminotransferase levels on spontaneous HBeAg seroconversion in chronic genotype B and C HBV-infected children","volume":"54","author":"Wu","year":"2012","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.cgh.2020.04.091_bib35","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.cgh.2007.01.005","article-title":"Chronic hepatitis B virus carriers in the immunotolerant phase of infection: histologic findings and outcome","volume":"5","author":"Andreani","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2020.04.091_bib36","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1038\/s41598-019-39043-2","article-title":"Comparison between chronic hepatitis B patients with untreated immune-tolerant phase vs those with virological response by antivirals","volume":"9","author":"Lee","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.cgh.2020.04.091_bib37","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1002\/hep.23424","article-title":"Efficacy of entecavir in chronic hepatitis B patients with mildly elevated alanine aminotransferase and biopsy-proven histological damage","volume":"51","author":"Wu","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2020.04.091_bib38","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/hep.28015","article-title":"Randomized, controlled trial of entecavir versus placebo in children with hepatitis B envelope antigen-positive chronic hepatitis B","volume":"63","author":"Jonas","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2020.04.091_bib39","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1053\/j.gastro.2009.08.061","article-title":"Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa","volume":"137","author":"Buster","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2020.04.091_bib40","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1053\/j.gastro.2014.01.044","article-title":"Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA","volume":"146","author":"Chan","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2020.04.091_bib41","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/MCG.0000000000000852","article-title":"Four-year outcomes after cessation of tenofovir in immune-tolerant chronic hepatitis B patients","volume":"52","author":"Wong","year":"2018","journal-title":"J\u00a0Clin Gastroenterol"},{"key":"10.1016\/j.cgh.2020.04.091_bib42","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1002\/hep.30312","article-title":"Combination of entecavir\/peginterferon alfa-2a in children with hepatitis B e antigen-positive immune tolerant chronic hepatitis B virus infection","volume":"69","author":"Rosenthal","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2020.04.091_bib43","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1002\/hep.30417","article-title":"Entecavir and peginterferon alfa-2a in adults with hepatitis B e antigen-positive immune-tolerant chronic hepatitis B virus infection","volume":"69","author":"Feld","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2020.04.091_bib44","doi-asserted-by":"crossref","first-page":"e50","DOI":"10.1097\/MCG.0b013e3182a9a2e1","article-title":"Predictors of significant fibrosis in chronic hepatitis B patients with low viremia","volume":"48","author":"Abdo","year":"2014","journal-title":"J\u00a0Clin Gastroenterol"},{"key":"10.1016\/j.cgh.2020.04.091_bib45","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/liv.13489","article-title":"Non-invasive tests for liver disease severity and the hepatocellular carcinoma risk in chronic hepatitis B patients with low-level viremia","volume":"38","author":"Paik","year":"2018","journal-title":"Liver Int"},{"key":"10.1016\/j.cgh.2020.04.091_bib46","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/apt.15311","article-title":"High risk of clinical events in untreated HBeAg-negative chronic hepatitis B patients with high viral load and no significant ALT elevation","volume":"50","author":"Choi","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2020.04.091_bib47","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1002\/hep.29213","article-title":"A\u00a0potent hepatitis B surface antigen response in subjects with inactive hepatitis B surface antigen carrier treated with pegylated-interferon alpha","volume":"66","author":"Cao","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2020.04.091_bib48","doi-asserted-by":"crossref","first-page":"191","DOI":"10.7326\/0003-4819-118-3-199302010-00006","article-title":"The natural history of asymptomatic hepatitis B surface antigen carriers","volume":"118","author":"de Franchis","year":"1993","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cgh.2020.04.091_bib49","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S0168-8278(02)00004-1","article-title":"Serum hepatitis B virus DNA levels and liver histology in inactive HBsAg carriers","volume":"36","author":"Martinot-Peignoux","year":"2002","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2020.04.091_bib50","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/0016-5085(94)90760-9","article-title":"A\u00a0long-term follow-up study of asymptomatic hepatitis B surface antigen-positive carriers in Montreal","volume":"106","author":"Villeneuve","year":"1994","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2020.04.091_bib51","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1002\/hep.21612","article-title":"HBsAg seroclearance in asymptomatic carriers of high endemic areas: appreciably high rates during a long-term follow-up","volume":"45","author":"Chu","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2020.04.091_bib52","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1053\/j.gastro.2004.06.021","article-title":"Natural history of chronic HBV carriers in northern Italy: morbidity and mortality after 30 years","volume":"127","author":"Manno","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2020.04.091_bib53","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1002\/hep.22878","article-title":"Long-term outcome of hepatitis B e antigen-negative hepatitis B surface antigen carriers in relation to changes of alanine aminotransferase levels over time","volume":"49","author":"Tai","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2020.04.091_bib54","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1053\/j.gastro.2010.01.042","article-title":"Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death","volume":"138","author":"Chen","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2020.04.091_bib55","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/j.cgh.2016.01.019","article-title":"Repeated measurements of hepatitis B surface antigen identify carriers of inactive HBV during long-term follow-up","volume":"14","author":"Brouwer","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2020.04.091_bib56","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/hep.26041","article-title":"Serum hepatitis B surface antigen levels help predict disease progression in patients with low hepatitis B virus loads","volume":"57","author":"Tseng","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2020.04.091_bib57","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/hep.28552","article-title":"Serum levels of hepatitis B surface antigen and DNA can predict inactive carriers with low risk of disease progression","volume":"64","author":"Liu","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2020.04.091_bib58","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/S2468-1253(17)30083-3","article-title":"Peg-interferon plus nucleotide analogue treatment versus no treatment in patients with chronic hepatitis B with a low viral load: a randomised controlled, open-label trial","volume":"2","author":"de Niet","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2020.04.091_bib59","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1136\/gutjnl-2013-306409","article-title":"Patients with chronic hepatitis B treated with oral antiviral therapy retain a higher risk for HCC compared with patients with inactive stage disease","volume":"63","author":"Cho","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2020.04.091_bib60","first-page":"580A","article-title":"Low incidence of clinical outcomes in patients with chronic HBV infection in the era of nucleos(t)ide analogue (NA) therapy: report from the Hepatitis B Research Network (HBRN) adult cohort study","volume":"70","author":"Lok","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2020.04.091_bib61","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/jvh.12643","article-title":"Determination of hepatitis B phenotype using biochemical and serological markers","volume":"24","author":"Di Bisceglie","year":"2017","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.cgh.2020.04.091_bib62","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1111\/apt.14613","article-title":"Anti-viral therapy can be delayed or avoided in a significant proportion of HBeAg-negative Caucasian patients in the grey zone","volume":"47","author":"Bonacci","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2020.04.091_bib63","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.14309\/ajg.0000000000000400","article-title":"Phase transition is infrequent among North American adults with e-antigen-negative chronic hepatitis B and low-level viremia","volume":"114","author":"Zhou","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2020.04.091_bib64","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1111\/liv.13416","article-title":"Long-term outcome of inactive and active, low viraemic HBeAg-negative-hepatitis B virus infection: benign course towards HBsAg clearance","volume":"37","author":"Oliveri","year":"2017","journal-title":"Liver Int"},{"key":"10.1016\/j.cgh.2020.04.091_bib65","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.cgh.2014.07.019","article-title":"Outcomes of patients with chronic hepatitis B who do not meet criteria for antiviral treatment at presentation","volume":"13","author":"Yapali","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2020.04.091_bib66","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1002\/hep.22476","article-title":"Treatment recommendations for chronic hepatitis B: an evaluation of current guidelines based on a natural history study in the United States","volume":"48","author":"Tong","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2020.04.091_bib67","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.jhep.2019.01.037","article-title":"The WHO guidelines for chronic hepatitis B fail to detect half of the patients in need of treatment in Ethiopia","volume":"70","author":"Aberra","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2020.04.091_bib68","doi-asserted-by":"crossref","first-page":"e4433","DOI":"10.1097\/MD.0000000000004433","article-title":"Lower liver cancer risk with antiviral therapy in chronic hepatitis B patients with normal to minimally elevated ALT and no cirrhosis","volume":"95","author":"Hoang","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.cgh.2020.04.091_bib69","doi-asserted-by":"crossref","DOI":"10.14309\/ctg.0000000000000036","article-title":"Prognosis of untreated minimally active chronic hepatitis B patients in comparison with virological responders by antivirals","volume":"10","author":"Lee","year":"2019","journal-title":"Clin Transl Gastroenterol"},{"key":"10.1016\/j.cgh.2020.04.091_bib70","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/hep.27382","article-title":"Comparison of diagnostic accuracy of aspartate aminotransferase to platelet ratio index and fibrosis-4 index for detecting liver fibrosis in adult patients with chronic hepatitis B virus infection: a systemic review and meta-analysis","volume":"61","author":"Xiao","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2020.04.091_bib71","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.jhep.2015.11.012","article-title":"Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients","volume":"64","author":"Kim","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2020.04.091_bib72","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/ajg.2010.463","article-title":"Mild-to-moderate elevation of alanine aminotransferase increases liver stiffness measurement by transient elastography in patients with chronic hepatitis B","volume":"106","author":"Fung","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2020.04.091_bib73","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJMoa051285","article-title":"A\u00a0comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B","volume":"354","author":"Chang","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2020.04.091_bib74","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.cgh.2019.07.010","article-title":"Outcomes of long-term treatment of chronic HBV infection with entecavir or other agents from a randomized trial in 24 countries","volume":"18","author":"Hou","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2020.04.091_bib75","doi-asserted-by":"crossref","first-page":"e125","DOI":"10.1038\/ctg.2017.51","article-title":"Seven-year treatment outcome of entecavir in a real-world cohort: effects on clinical parameters, HBsAg and HBcrAg levels","volume":"8","author":"Lam","year":"2017","journal-title":"Clin Transl Gastroenterol"},{"key":"10.1016\/j.cgh.2020.04.091_bib76","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1056\/NEJMoa0802878","article-title":"Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B","volume":"359","author":"Marcellin","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2020.04.091_bib77","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S2468-1253(16)30024-3","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial","volume":"1","author":"Chan","year":"2016","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2020.04.091_bib78","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.jhep.2017.11.039","article-title":"96 weeks treatment of tenofovir alafenamide vs tenofovir disoproxil fumarate for hepatitis B virus infection","volume":"68","author":"Agarwal","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2020.04.091_bib79","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJMoa040431","article-title":"Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B","volume":"351","author":"Marcellin","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2020.04.091_bib80","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1007\/s12072-012-9343-x","article-title":"Hepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients","volume":"7","author":"Marcellin","year":"2013","journal-title":"Hepatol Int"},{"key":"10.1016\/j.cgh.2020.04.091_bib81","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1056\/NEJMoa051287","article-title":"Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B","volume":"354","author":"Lai","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2020.04.091_bib82","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S2468-1253(16)30107-8","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial","volume":"1","author":"Buti","year":"2016","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2020.04.091_bib83","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1053\/jhep.2002.34294","article-title":"Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B","volume":"36","author":"Perrillo","year":"2002","journal-title":"Hepatology"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356520306777?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356520306777?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:35:00Z","timestamp":1761543300000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356520306777"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":83,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S1542356520306777"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2020.04.091","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Should Treatment Indications for Chronic Hepatitis B Be Expanded?","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2020.04.091","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 by the AGA Institute","name":"copyright","label":"Copyright"}]}}